Analysts expect Kazia Therapeutics Ltd to report revenue of 0.00 for 2023, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 38,810.00, a 14.0% miss against the 45,115.68 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 11.00 M | 17,220.00 | - | - | 38,810.00 | ||||
| High Estimate | 17.02 M | 11,575.39 | 0.00 | 102,348.64 | 47,665.75 | ||||
| Low Estimate | 14.25 M | 10,228.07 | 0.00 | 90,616.36 | 42,565.61 | ||||
| Consensus Estimate | 15.64 M | 10,901.73 | 0.00 | 96,482.50 | 45,115.68 |
Analysts expect Kazia Therapeutics Ltd to report earnings per share of -31.81 for 2024, against a range of -34.23 to -29.39. The most recent reported year, 2025, came in at -1.23 , in line with the -0.01 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -25.94 | -64.08 | -36.25 | - | -1.23 | - | |||
| High Estimate | -21.77 | -57.54 | -35.78 | -29.39 | -0.01 | -1.00 | |||
| Low Estimate | -23.49 | -69.44 | -38.28 | -34.23 | -0.01 | -1.20 | |||
| Consensus Estimate | -22.63 | -63.49 | -37.03 | -31.81 | -0.01 | -1.10 |